BioXcel Therapeutics (BTAI) Cash from Investing Activities (2018 - 2022)
BioXcel Therapeutics' (BTAI) quarterly Cash from Investing Activities came in at -$19000.0 in Q2 2022, up 81.0% year-on-year from -$10497.2 in Q2 2021, and up 84.17% quarter-over-quarter from -$120000.0 in Q1 2022.
BioXcel Therapeutics (BTAI) Cash from Investing Activities (2018 - 2022) Analysis & Trends
BioXcel Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$19000.0 for Q2 2022.
- On a quarterly basis, Cash from Investing Activities rose 81.0% year-over-year to -$19000.0 in Q2 2022; TTM through Sep 2023 was -$19000.0, a 87.42% increase from a year earlier, with the FY2023 full-year figure at -$20000.0, up 85.61% from the prior year.
- Cash from Investing Activities improved to -$19000.0 in Q2 2022 per BTAI's latest filing, from -$120000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5000.0 in Q3 2020 and bottomed at -$600000.0 in Q1 2019.
- The 5-year median for Cash from Investing Activities is -$52500.0 (2018), against an average of -$124375.0.
- Biggest YoY gain for Cash from Investing Activities was 111.63% in 2020; the steepest drop was 13400.0% in 2020.
- Year by year, Cash from Investing Activities stood at -$158000.0 in 2018, then surged by 98.73% to -$2000.0 in 2019, then plunged by 13400.0% to -$270000.0 in 2020, then surged by 95.56% to -$12000.0 in 2021, then slumped by 58.33% to -$19000.0 in 2022.
- Per Business Quant, the three latest BTAI Cash from Investing Activities figures stand at -$19000.0 (Q2 2022), -$120000.0 (Q1 2022), and -$12000.0 (Q4 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | BioXcel Therapeutics | 20.57 Mn | 20.57 Mn | -77,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -19,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Sep 30, 2021 | -17,000.00 |
| Sep 30, 2021 | -17,000.00 |
| Jun 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -100,000.00 |
| Mar 31, 2021 | -316,000.00 |
| Mar 31, 2021 | -316,000.00 |
| Dec 31, 2020 | -270,000.00 |
| Dec 31, 2020 | -270,000.00 |
| Sep 30, 2020 | 5,000.00 |
| Sep 30, 2020 | 5,000.00 |
| Jun 30, 2020 | -35,000.00 |
| Jun 30, 2020 | -35,000.00 |
| Mar 31, 2020 | -16,000.00 |
| Mar 31, 2020 | -16,000.00 |